DB
TBIO

Dmitry Balyasny’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Dmitry Balyasny’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-275,000
Closed -$4.93M – 1700
2020
Q2 		$4.93M Buy
+275,000
New +$4.15M 0.04% 525

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dmitry Balyasny's TBIO Position: Q4 2020 in Review

Dmitry Balyasny sold out of Translate Bio, Inc. Common Stock (TBIO) in Q4 2020, closing a stake of 77,227 shares — an estimated $1.05M sold.

Dmitry Balyasny first reported a position in TBIO in Q2 2020 and held it in 2 quarters. The position peaked at $6.29M in Q2 2020. 150 funds tracked by Wall St. Rank hold TBIO as of Q4 2020.

  • Dmitry Balyasny reported no remaining Translate Bio, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Dmitry Balyasny sold 77,227 Translate Bio, Inc. Common Stock shares in Q4 2020, an estimated $1.05M.
  • Dmitry Balyasny first reported a position in Translate Bio, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Dmitry Balyasny's Translate Bio, Inc. Common Stock position peaked at $6.29M in Q2 2020.
  • 150 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q4 2020.

Based on Balyasny Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.